Connor, Clark & Lunn Investment Management Ltd. Novo Cure LTD Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Novo Cure LTD stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 610,714 shares of NVCR stock, worth $7.03 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

610,714

Previous 534,749 14.21%

Holding current value

$7.03 Million

Previous $9.53 Million 14.07%

% of portfolio

0.04%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	BUY	$15.37 - $19.4 $1.17 Million - $1.47 Million	75,965 Added 14.21%	610,714 $10.9 Million
Q1 2025 May 12, 2025	BUY	$17.82 - $30.19 $1.73 Million - $2.93 Million	96,977 Added 22.15%	534,749 $9.53 Million
Q4 2024 Feb 10, 2025	BUY	$14.54 - $33.41 $167,340 - $384,515	11,509 Added 2.7%	437,772 $13 Million
Q3 2024 Nov 08, 2024	BUY	$15.61 - $23.34 $930,480 - $1.39 Million	59,608 Added 16.26%	426,263 $6.66 Million
Q2 2024 Aug 09, 2024	BUY	$11.83 - $24.05 $618,448 - $1.26 Million	52,278 Added 16.63%	366,655 $6.28 Million
Q1 2024 May 09, 2024	SELL	$12.42 - $17.29 $1.18 Million - $1.65 Million	-95,223 Reduced 23.25%	314,377 $4.91 Million
Q4 2023 Feb 09, 2024	BUY	$11.13 - $15.78 $8,469 - $12,008	761 Added 0.19%	409,600 $6.12 Million
Q3 2023 Nov 13, 2023	BUY	$16.15 - $42.35 $5.48 Million - $14.4 Million	339,610 Added 490.56%	408,839 $6.6 Million
Q2 2023 Aug 10, 2023	BUY	$40.29 - $82.51 $2.42 Million - $4.95 Million	59,978 Added 648.34%	69,229 $2.87 Million
Q1 2023 May 09, 2023	BUY	$56.44 - $118.81 $522,126 - $1.1 Million	9,251 New	9,251 $556,000
Q2 2022 Aug 05, 2022	BUY	$56.6 - $89.9 $721,650 - $1.15 Million	12,750 New	12,750 $886,000

Others Institutions Holding NVCR

# of Institutions

265

Shares Held

79.2M

Call Options Held

970K

Put Options Held

118K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.21B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Novo Cure LTD Transaction History